trial

A Study of ANAVEX3-71 in Adults With Schizophrenia

NCTId NCT06245213
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 71 (actual)
Sponsored by Anavex Life Sciences Corp.
Primary completion 2025-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
71 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-03-15
Primary completion
2025-06-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ANAVEX3-71 oral capsules

Sponsors

Anavex Life Sciences Corp.Lead Sponsor
COGNISIONCollaborator
Cognitive Research CorporationCollaborator
Hassman Research InstituteCollaborator

Sites

1 total
Marlton, United States

Linked catalysts

1
A Study of ANAVEX3-71 in Adults With Schizophrenia — primary completion2025-06-30

Facts & assertions

4 sourced
Enrollment
71
Phase
PHASE2
Primary Completion Date
2025-06-30
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
ANAVEX3-71 oral capsules
drug
lead_sponsor
Anavex Life Sciences Corp.
company
collaborator
COGNISION
company
Cognitive Research Corporation
company
indication
Schizophrenia
indication
Schizophrenia
indication